论文部分内容阅读
目的:观察参莲胶囊联合同步放化疗治疗中晚期非小细胞肺癌的近期疗效和不良反应。方法:将72例中晚期非小细胞肺癌患者随机分为对照组和试验组各36例,2组均采用同步放化疗,放疗总量64~70GY/32~35F(6~7周),且在放疗期间给予EP方案(顺铂25mg/m2,d1~3天静脉滴注,足叶乙苷100mg/d,d1~5天静脉滴注)化疗2周期。试验组在上述基础上配合参莲胶囊6粒/次,1日3次,连用3个月。结果:试验组的近期有效率为81%,对照组为75%,试验组放化疗不良反应明显减轻,两组有差异(P<0.05)。结论:参莲胶囊联合同步放化疗治疗中晚期肺癌患者不良反应轻,能提高患者生存质量。
Objective: To observe the short-term curative effect and adverse reaction of Shenlian capsule combined with concurrent chemoradiotherapy in the treatment of advanced non-small cell lung cancer. Methods: Seventy-two patients with advanced non-small cell lung cancer were randomly divided into control group and trial group, with 36 cases in each group. Both groups received concurrent chemoradiotherapy. The total amount of radiotherapy was 64-70GY / 32-35F (6-7 weeks) During the radiotherapy EP program (cisplatin 25mg / m2, d1 ~ 3 days intravenous infusion, etoposide 100mg / d, d1 ~ 5 days intravenous infusion) 2 cycles of chemotherapy. The experimental group on the basis of the above with lotus capsules 6 capsules / time, 3 times a day, once every 3 months. Results: The effective rate was 81% in the trial group and 75% in the control group. Adverse reaction to radiotherapy and chemotherapy in the experimental group was significantly reduced (P <0.05). Conclusion: Shen Lian Capsule combined with concurrent chemoradiotherapy in patients with advanced lung cancer patients with mild adverse reactions, can improve the quality of life of patients.